FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)									1					
1. Name and Address of Reporting Person * CONRAD HERBERT J				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
	ΓΙΝΑS ΒΙ		(Middle) A HOLDINGS, TH SUITE 302	3. Date of Earlies 03/31/2019	t Tran	sactio	on (M	onth/Day	//Year)		Office	er (give title belo	ow)	Other (spec	fy below	v)
BEDMIN	ISTER, N.	(Street)		4. If Amendment	, Date	Origi	nal Fi	iled(Month	n/Day/Year)		_X_ Form fil	ual or Joint/O led by One Repo ed by More than	orting Person	-	licable L	ine)
(City)		(State)	(Zip)	T	able I	- Noi	n-Der	ivative S	Securities	Acqu	ired, Disp	osed of, or I	Beneficially	Owned		
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	(Instr. 8)		ction			of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownersh Form: Direct (D	of I Ber	Nature Indirect neficial mership		
				(Monun/Day/Year		ode	V	Amoun	(A) or (D)	Price	(mstr. 3 ar	nd 4)		or Indirect (I) (Instr. 4)	-	str. 4)
Common	nmon Stock 03/31/2019			1	A		22,019 (1)	A	\$ 0 122,019			D				
Common		separate line fo	or each class of secu	rities beneficially o	wned		Pers cont	ons whained in	o respon	rm ar	e not requ	ction of inf	spond unl	ess	J. C Tru u/a 3/4 He Co and Jud Co Tru	rbert Conrad ust //d //2005, rbert J nrad
											•	OMB cont	trol numb	er.		
				Derivative Securit (e.g., puts, calls, w		_		-			•					
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/	Year) Execution Da	te, if Transaction Code	5. Numl of Deriv Secur Acqu (A) o Dispo of (D (Instr 4, and	vative rities ired r osed)	and (Mo	ate Exer Expirationth/Day/	on Date	Am Und Sec	Title and ount of derlying urities str. 3 and	8. Price of Derivative Security (Instr. 5)		Own Form Derig Secu Direct or In	of vative rity: et (D) direct	11. Natu of Indire Benefici Ownersh (Instr. 4)
				Code V	(A)	(D)	Date Exe		Expiration Date	n Titl	Amount or e Number of Shares					

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		

TINAS BIOPHARMA HOLDINGS, INC. UTE 206 SOUTH SUITE 302 NSTER, NJ 07921
--

Signatures

/s/ Jerome D. Jabbour, attorney-in-fact for Herbert J. Conrad	04/03/2019	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 31, 2019, the Reporting Person was issued 22,019 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.